Dataset Information


ROR-γ drives androgen-receptor expression and represents a therapeutic target in castration-resistant prostate cancer

ABSTRACT: The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor–related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR–ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa. Overall design: A total of 16 samples were analyzed in this study. The study included one cell line C4-2B. C4-2B cells were cultured in medium containing vehicle control or SR2211 (5 µM) for 24 hours, cells then were collected for ChIP seq assay

INSTRUMENT(S): Illumina HiSeq 2000 (Homo sapiens)

ORGANISM(S): Homo sapiens  

SUBMITTER: Junjian Wang  




Dataset's files

Action DRS
GSE72714_RAW.tar Raw
filelist.txt Txt
Items per page:
1 - 2 of 2

Similar Datasets

2016-03-08 | E-GEOD-72483 | ArrayExpress
2016-03-08 | E-GEOD-72714 | ArrayExpress
2016-01-01 | S-EPMC5030109 | BioStudies
2020-01-01 | S-EPMC7335377 | BioStudies
2017-01-01 | S-EPMC5505214 | BioStudies
2020-01-01 | S-EPMC7745055 | BioStudies
2017-01-01 | S-EPMC5354662 | BioStudies
2020-01-01 | S-EPMC7408918 | BioStudies
2016-01-01 | S-EPMC5325444 | BioStudies
2011-01-01 | S-EPMC3228103 | BioStudies